December 17, 2020 07:47 AM ESTUpdated 11:32 AM
Financing

The biotech IPO train keeps chug­ging, as Virios prices $30M pub­lic de­but

Nicole DeFeudis

Editor

Chest­nuts roast­ing on an open fire, biotechs keep pric­ing IPOs.

Virios Ther­a­peu­tics priced its pub­lic de­but on Thurs­day, bring­ing home $30 mil­lion and con­tribut­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times